Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C and HIV Coinfection => Topic started by: Hep Editors on March 27, 2017, 10:10:50 am
-
AbbVie’s experimental hepatitis C virus (HCV) regimen, glecaprevir/pibrentasvir, known as G/P, is safe for use with common antiretroviral regimens for HIV, aidsmap reports. A small study found that dose adjustments are not necessary when pairing G/P with Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) or Triumeq (dolutegravir/abacavir/lamivudine).
In February, AbbVie applied for U.S. Food and Drug Administration (FDA) approval of G/P, which the FDA has granted priority review status. A decision is expected in late June.
For more...
https://www.hepmag.com/article/abbvies-hep-c-treatment-glecaprevirpibrentasvir-safe-major-hiv-regimens